ES2371287T3 - Expresión diferencial de la citocina en cáncer humano. - Google Patents
Expresión diferencial de la citocina en cáncer humano. Download PDFInfo
- Publication number
- ES2371287T3 ES2371287T3 ES07764767T ES07764767T ES2371287T3 ES 2371287 T3 ES2371287 T3 ES 2371287T3 ES 07764767 T ES07764767 T ES 07764767T ES 07764767 T ES07764767 T ES 07764767T ES 2371287 T3 ES2371287 T3 ES 2371287T3
- Authority
- ES
- Spain
- Prior art keywords
- tumor
- cytokine
- agent
- cells
- neutralizing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 137
- 201000011510 cancer Diseases 0.000 title claims abstract description 47
- 230000014509 gene expression Effects 0.000 title claims abstract description 45
- 102000004127 Cytokines Human genes 0.000 claims abstract description 92
- 108090000695 Cytokines Proteins 0.000 claims abstract description 92
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 43
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 37
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 36
- 230000002424 anti-apoptotic effect Effects 0.000 claims abstract description 32
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 30
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 102000004388 Interleukin-4 Human genes 0.000 claims description 80
- 239000003795 chemical substances by application Substances 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000003472 neutralizing effect Effects 0.000 claims description 34
- 238000011282 treatment Methods 0.000 claims description 33
- 210000001072 colon Anatomy 0.000 claims description 26
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 210000000481 breast Anatomy 0.000 claims description 21
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 208000029742 colonic neoplasm Diseases 0.000 claims description 19
- 230000002496 gastric effect Effects 0.000 claims description 19
- 206010009944 Colon cancer Diseases 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 13
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 10
- 229960001756 oxaliplatin Drugs 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 8
- 210000003932 urinary bladder Anatomy 0.000 claims description 8
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 7
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 230000001640 apoptogenic effect Effects 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 230000027455 binding Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 2
- 230000000970 DNA cross-linking effect Effects 0.000 claims description 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000003667 hormone antagonist Substances 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000000984 immunochemical effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000000138 intercalating agent Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 4
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000030833 cell death Effects 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 102100034691 Astrocytic phosphoprotein PEA-15 Human genes 0.000 description 11
- 101000734668 Homo sapiens Astrocytic phosphoprotein PEA-15 Proteins 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 230000003305 autocrine Effects 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 8
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 7
- 229960004679 doxorubicin Drugs 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 102000055229 human IL4 Human genes 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 210000005265 lung cell Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010049207 Death Domain Receptors Proteins 0.000 description 4
- 102000009058 Death Domain Receptors Human genes 0.000 description 4
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 4
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000005170 neoplastic cell Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 3
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108010067988 prolactin-binding protein Proteins 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 2
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150038592 GAPD gene Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020941 Interleukin-4 Human genes 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000019207 human interleukin-13 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108040006870 interleukin-10 receptor activity proteins Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229950011485 pascolizumab Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 108010010907 pitrakinra Proteins 0.000 description 1
- 229950008185 pitrakinra Drugs 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06012754 | 2006-06-21 | ||
| EP06012754 | 2006-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2371287T3 true ES2371287T3 (es) | 2011-12-29 |
Family
ID=38359749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07764767T Active ES2371287T3 (es) | 2006-06-21 | 2007-06-21 | Expresión diferencial de la citocina en cáncer humano. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090324616A1 (fr) |
| EP (1) | EP2041576B1 (fr) |
| JP (1) | JP2010514409A (fr) |
| CN (1) | CN101529253A (fr) |
| AT (1) | ATE520032T1 (fr) |
| AU (1) | AU2007263265A1 (fr) |
| BR (1) | BRPI0713484A2 (fr) |
| CA (1) | CA2656379A1 (fr) |
| DK (1) | DK2041576T3 (fr) |
| ES (1) | ES2371287T3 (fr) |
| RU (1) | RU2009101783A (fr) |
| WO (1) | WO2007147600A2 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2646626A1 (fr) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Anticorps specifique de l'il-4 humaine pour le traitement du cancer |
| AU2007271349A1 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| DK3409686T3 (da) * | 2012-07-18 | 2022-07-18 | Apogenix Ag | Sammensætning omfattende en blanding af cd95-fc-isoformer |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| EP3209382B1 (fr) * | 2014-10-24 | 2020-11-25 | Calidi Biotherapeutics, Inc. | Technique d'immunotherapie combinee pour le traitement du cancer |
| CN115212301A (zh) | 2015-08-11 | 2022-10-21 | 卡利迪生物治疗有限公司 | 用以癌症治疗的天花疫苗 |
| EA038551B1 (ru) | 2015-12-17 | 2021-09-14 | Дзе Джонс Хопкинс Юниверсити | Способ лечения или профилактики системного склероза |
| KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| EP4053557A1 (fr) * | 2016-11-24 | 2022-09-07 | Huvet Bio, Inc. | Il-29 comme marqueur d'une maladie du pancréas |
| CA3071661A1 (fr) * | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Recepteurs chimeriques specifiques d'etiquette strep et utilisations de ceux-ci |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU643427B2 (en) * | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| DE4137333A1 (de) * | 1991-11-13 | 1993-05-19 | W Prof Dr Sebald | Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung |
| US6534051B1 (en) * | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| NZ274338A (en) | 1993-09-07 | 1998-02-26 | Smithkline Beecham Corp | Chimeric and humanised il-4 monoclonal antibodies and their use |
| DE4423131A1 (de) * | 1994-07-01 | 1996-01-04 | Bayer Ag | Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4 |
| RU2218348C2 (ru) * | 1994-07-05 | 2003-12-10 | Стено Рисерч Груп А/С | Полипептид с il-10 подобными свойствами (варианты), конъюгат полипептида, фармацевтическая композиция, способ модуляции иммунного ответа у млекопитающего |
| HUT76369A (en) * | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US20030124125A1 (en) * | 1996-04-05 | 2003-07-03 | South Alabama Medical Science Foundation | Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10 |
| US6028176A (en) * | 1996-07-19 | 2000-02-22 | Bayer Corporation | High-affinity interleukin-4 muteins |
| EP1029550A4 (fr) * | 1997-11-10 | 2001-09-26 | Mochida Pharm Co Ltd | Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses |
| JPH11312463A (ja) * | 1998-04-28 | 1999-11-09 | Hitachi Ltd | 配線基板およびそれを用いたガス放電型表示装置 |
| CN1981868A (zh) * | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| WO2002004009A2 (fr) * | 2000-07-12 | 2002-01-17 | Immunex Corporation | Methode de traitement du cancer |
| US20040023338A1 (en) * | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
| US20040023337A1 (en) * | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| EP1444989A1 (fr) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| CA2587903A1 (fr) * | 2004-11-17 | 2006-05-26 | Amgen Fremont Inc. | Anticorps monoclonaux entierement humains diriges contre l'il-13 |
| US20070122855A1 (en) * | 2005-11-28 | 2007-05-31 | Targetgen Inc. | Methods for diagnosing hepatocellular carcinoma |
| CA2646626A1 (fr) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Anticorps specifique de l'il-4 humaine pour le traitement du cancer |
| AU2007271349A1 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
-
2007
- 2007-06-21 BR BRPI0713484-3A patent/BRPI0713484A2/pt not_active IP Right Cessation
- 2007-06-21 CN CNA2007800295788A patent/CN101529253A/zh active Pending
- 2007-06-21 EP EP07764767A patent/EP2041576B1/fr active Active
- 2007-06-21 WO PCT/EP2007/005480 patent/WO2007147600A2/fr active Application Filing
- 2007-06-21 ES ES07764767T patent/ES2371287T3/es active Active
- 2007-06-21 RU RU2009101783/15A patent/RU2009101783A/ru not_active Application Discontinuation
- 2007-06-21 AU AU2007263265A patent/AU2007263265A1/en not_active Abandoned
- 2007-06-21 US US12/306,070 patent/US20090324616A1/en not_active Abandoned
- 2007-06-21 JP JP2009515770A patent/JP2010514409A/ja active Pending
- 2007-06-21 CA CA002656379A patent/CA2656379A1/fr not_active Abandoned
- 2007-06-21 AT AT07764767T patent/ATE520032T1/de not_active IP Right Cessation
- 2007-06-21 DK DK07764767.5T patent/DK2041576T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007263265A1 (en) | 2007-12-27 |
| CA2656379A1 (fr) | 2007-12-27 |
| ATE520032T1 (de) | 2011-08-15 |
| WO2007147600A2 (fr) | 2007-12-27 |
| US20090324616A1 (en) | 2009-12-31 |
| EP2041576A2 (fr) | 2009-04-01 |
| BRPI0713484A2 (pt) | 2012-11-06 |
| JP2010514409A (ja) | 2010-05-06 |
| WO2007147600A3 (fr) | 2008-04-10 |
| EP2041576B1 (fr) | 2011-08-10 |
| RU2009101783A (ru) | 2010-07-27 |
| DK2041576T3 (da) | 2011-12-05 |
| CN101529253A (zh) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2371287T3 (es) | Expresión diferencial de la citocina en cáncer humano. | |
| Silva-Santos et al. | γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer | |
| Wei et al. | Tumor microenvironment regulation by the endoplasmic reticulum stress transmission mediator Golgi protein 73 in mice | |
| ES2420582T3 (es) | La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo | |
| US20150118244A1 (en) | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients | |
| AU2014217611A1 (en) | Therapeutic and diagnostic target for cancer comprising DLL3 binding reagents | |
| JP2006519190A (ja) | サイトカインを選択的にブロックすることによる、アポトーシスに対する感作細胞 | |
| JP7032396B2 (ja) | Ｔ細胞応答を促進するための方法 | |
| JP2016501843A (ja) | 癌治療および判断ターゲットとしてのｌｙ７５ | |
| Kiewlich et al. | Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth | |
| KR20140004552A (ko) | 페리오스틴에 대한 압타머 및 이를 포함하는 항암제 조성물 | |
| CN111781359A (zh) | 用于预测免疫疗法的临床效果的方法 | |
| KR20210136071A (ko) | 암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제 | |
| Liu et al. | Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma | |
| CN107249636B (zh) | 以ckap4作为靶分子的抗肿瘤剂 | |
| EP3558359A1 (fr) | Immunocytokines avec mécanisme d'activation progressive | |
| US20220056123A1 (en) | Use of il-1beta binding antibodies | |
| CA3076997C (fr) | Anticorps monoclonal anti-ckap4 | |
| Wu | Circulating tumor markers of the new millennium: target therapy, early detection, and prognosis | |
| ES2868998T3 (es) | Anticuerpo biespecífico que se une a NAALADL2 Y CD3 para el uso como agente terapéutico en el tratamiento del cáncer de próstata | |
| EP2924117B1 (fr) | Nouvel anticorps humain contre il-18 | |
| US20170247469A1 (en) | Modulation of ptpra to treat arthritis | |
| O’Donovan et al. | Chemokine-targeted therapies: An opportunity to remodel immune profiles in gastro-oesophageal tumours | |
| CN114908158B (zh) | Cdk1在晚期胃肠间质瘤的诊断和治疗中的应用 | |
| ES2937862T3 (es) | Predicción de respondedores a terapia con ciclofosfamida |